Data Foundry

Drug recalls 2023

Tacrolimus Capsules — Class II drug recall D-0330-2023

Ongoing recall by Dr. Reddy's Laboratories, Inc., reported 2023-03-01, distributed nationwide. Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containin

Recall numberD-0330-2023
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmDr. Reddy's Laboratories, Inc., Princeton, NJ, United States
Recall initiated2023-02-08
Classified2023-02-21
Reported by FDA2023-03-01
DistributedNationwide (US)
Quantity4,320 bottles
Reason classeslabeling
NDC55111-0525, 55111-0525-01, 55111-0525-05, 55111-0525-30, 55111-0525-78, 55111-0525-79, 55111-0526, 55111-0526-01, 55111-0526-05, 55111-0526-30, 55111-0526-78, 55111-0526-79, 55111-0527, 55111-0527-01, 55111-0527-05, 55111-0527-30, 55111-0527-78, 55111-0527-79
Lot numbersC2106445
Expiration dates2024-03

Product

Tacrolimus Capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Mfd. by Dr. Reddy's Laboratories Limited, Bachupally - 500 090, INDIA; NDC 55111-525-01.

Reason for recall

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0330-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.